NASDAQ:GOSS

Gossamer Bio Stock Predictions

etoro logo Buy GOSS
*Your capital is at risk
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

GOSS Prediction Chart

GOSS Predictions History

Latest community submissions for GOSS.
Predictor Target Session Target Price Result Direction Accuracy Score
skovarza skovarza @skovarza.209071
Feb 17, 2021 $15.00 +37.87% $10.88 X 62.07% 1
JS JS Pro
Feb 16, 2021 $10.50 -2.69% $10.79 X 97.31% 0
David Atwood David Atwood @DavidAtwood.209150
Feb 16, 2021 Bullish $10.79 X 1
JS JS Pro
Dec 15, 2020 $10.55 -3.03% $10.88 X 96.97% 0
CORealtor CORealtor Merchant
Dec 15, 2020 $10.80 -0.74% $10.88 X 99.26% 4
JS JS Pro
May 26, 2020 $12.74 +2.17% $12.47 X 97.83% 0
May 26, 2020 Bearish $12.47 X 1
JS JS Pro
Jan 6, 2020 $15.09 -0.07% $15.10 X 99.93% 10
Александр Кузнецов Александр Кузнецов @D090D0BBD0B5D0BAD181D0B0D0BDD0B4D180D09AD183D0B7D0BDD0B5D186D0BED0B2.132526
Jan 6, 2020 $15.37 +1.79% $15.10 X 98.21% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for GOSS with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT GOSSAMER BIO INC.
Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE